CU cancer members recognized for contributions to immunotherapy in pediatric cancer eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Kenneth Grossmann, MD, PhD, of Huntsman Cancer Institute, led the SWOG S1404 clinical trial, which found that patients with high-risk melanoma who had pembrolizumab after their surgery had a longer. view more
Credit: Huntsman Cancer Institute
PORTLAND, OR - Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021.
Researchers also measured overall survival and found no statistically significant difference in overall survival rates between the two groups of patients three and one-half years after the last patient enrolled to the trial. They did find, however, that patients taking pembrolizumab had fewer serious side effects than those treated with either high-dose in
Last year, I did several posts on what I consider to be a profoundly misguided and potentially harmful type of law known as "right-to-try." Beginning about a year and a half ago, promoted by the libertarian think tank known as the Goldwater Institute, right-to-try laws began popping up in state legislatures.
Milk Thistle a Proven Cancer-Fighter and Liver-Supporter
2.9Kshares
November 21, 2013
November 21, 2013
Milk thistle has been used for thousands of years as a medicinal plant. It is native to the Mediterranean region but can now be found throughout the world. It’s generally seen as beneficial for liver, kidney, and gallbladder issues, but research in recent years indicates it may do even more.
Silymarin, a substance within milk thistle, is largely credited with its benefits. It has both antioxidant and anti-inflammatory properties and could be the leading cause of milk thistle’s benefits. Scientists isolating and researching this compound has led to milk thistle being approved for treating liver disease back in 1986, a considerable achievement for a natural substance in this world that worships Big Pharma above all.
Novartis has lost another NIBR exec to the call of biotech. Blueprint Medicines has added another BMS vet to its roster. And Iovance quietly announced its CEO's departure Wednesday.